BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results